[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_9352",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_9352"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB08907"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "invokana r as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of major adverse cardiovascular events cardiovascular death nonfatal myocardial infarction and nonfatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease cvd invokana is a sodium glucose co transporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease 1 limitations of use not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis 1 limitations of use invokana is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB08907",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-12T14:45:11.988+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "jCpcdTRGxE5e81fArhExhvhEVZdZh3d4XKSf2m8NpkPgflhhL0j5IAQyY/96RwmEKiFvjoYUFzymoXfzxf+A70mS8AgmttfkkW5Hen7jFviL/hOGX6CL4ZzHL536LcnpnxEkoV/ynrFFL6XFEDf9sWNCMh7ip1RUvFod+zvjSKA="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#pubinfo"
} ]